A Phase 3 interventional study of In open-label phase: treatment with tofacitinib and In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio in Arthritis Juvenile Idiopathic, sponsored by Pfizer. Completed at 52 sites in 19 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-06-03.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arthritis, Juvenile by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Juvenile · Pfizer.
Among the 10 studies in Arthritis, Juvenile by Pfizer, this one is the only one that started in 2018, is one of 4 in phase 3, and was the 9th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →1 of the 10 studies in Arthritis, Juvenile by Pfizer is open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of
Ages 2–17
By country, each count listing its studies:
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 5 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 52 across 230 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 127 across the 7 interventional studies, 100 across the 3 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Arthritis, Juvenile by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA flare. An interim analysis for efficacy and futility will be conducted when at least 20 flares have been observed. If either criterion is met, the study will be stopped. If neither criterion is met, the study will continue until the requisite number of flares are observed as determined by the number of flares included in the interim analysis and a statistical penalty for conducting the interim analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
oral, twice daily, tablet or solution.
Drug: In open-label phase: treatment with tofacitinib · Drug: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
Drug: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
Drug page: Tofacitinib
Treatment with investigational drug
Also known as: CP-690,550, Xeljanz
Treatment with investigational drug or placebo
Also known as: CP-690,550, Xeljanz
Time to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind Phase
Time to the disease flare=the number of days from randomization to flare in the DB phase and calculated as date of disease flare minus (-) date of randomization plus (+) 1. sJIA Flare=as at least one of the following criteria: Recurrence of fever \>38 degree Celsius (C)/100.4 degree Fahrenheit (F) on 2 or more consecutive days) was considered due to SJIA activity. Worsening of 30 percent (%) or more in three or more of the six variables included: Number of joints with active arthritis and limited range of motion, disease activity, parent child evaluation of overall well-being, functional ability, childhood health assessment questionnaire ( CHAQ disability index), erythrocyte sedimentation rate (ESR) millimeter/ hour (mm/hr), of the JIA core set with no more than one variable of the JIA core set improving by 30% compared to the day of randomization into the withdrawal phase. 95% Confidence Interval (CI) based on Brookmeyer and Crowley Method.
Time frame: From randomization up to 248 weeks
Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase
sJIA Flare was defined as at least one of the following criteria: recurrence of fever (\>38° C/100.4 degree F) on 2 or more consecutive days) was considered due to SJIA activity. Worsening of 30% or more in three or more of the six variables: number of joints with active arthritis and limited range of motion, disease activity, parent child evaluation of overall well-being, functional ability (CHAQ Disability Index), ESR. of the JIA core set with no more than one variable of the JIA core set improving by 30% compared to the day of randomization into the withdrawal phase. Probability of occurrence of sJIA disease flare with 95% CI were estimated using Kaplan-Meier method and reported in this outcome measure.
Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Percentage of Participants Who Achieved Successful Corticosteroid Tapering: at the End of Open-label Phase Part 2
A successfully tapered participant was considered as the one that completed part 2 of the OL by reaching their target corticosteroid dose and maintained an adapted JIA American College of Rheumatology (ACR) 30 response for four weeks on this dose. The target CS dose at the end of part 2 included less than equal to (\<=) 0.5 milligram/kilogram/day (mg/kg/day) up to a maximum dose of 15 milligram/ day (mg/day) oral prednisone (or equivalent) for CS\>0.8 mg/kg/day oral prednisone; reduction to \<=0.3 mg/kg/day up to a maximum of 12 mg/day oral prednisone (or equivalent) for CS \<=0.8 mg/kg/day to greater than equal to (\>=) 0.5 mg/kg/day oral prednisone (or equivalent) and \<=0.2 mg/kg/day up to a maximum dose of 10 mg/day oral prednisone (or equivalent) for CS \<0.5 mg/kg/day-CS˃0.2 mg/kg/day oral prednisone (or equivalent). 95% CI was based on normal approximation.
Time frame: From end of OL Part 1 to up to 24 weeks in OL Part 2
Percentage of Participants Who Achieved Corticosteroid Dose of <= 0.2 mg/kg/Day or 10 mg/Day: at the End of Open-label Phase Part 2
95% CI was based on normal approximation.
Time frame: From end of OL Part 1 to up to 24 weeks in OL Part 2
Percentage of Participants With Adapted JIA ACR 30/50/70/90/100 Response at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of \>=30,50,70,90,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by \>=30%.Variables included: number of joints with active arthritis(any joint with swelling, or absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on VAS from 0=no disease activity to 10=very severe disease activity, higher scores:greater disease activity; parent/legal guardian/child evaluation of overall well-being on VAS from 0=very well to 10mm=very poor, higher scores: worsen condition; functional ability (Disability Index ranged from 0=no or minimal physical dysfunction, 3=very severe physical dysfunction, higher scores:more physical dysfunction;ESR (mm/hr).Missing response was imputed as non-response.
Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Percentage of Participants With Adapted JIA American College of Rheumatology (ACR) 30/50/70/90/100 Response at Part 1 Day 7, Weeks 2, 4, 8, 12, and 16: Open-Label Phase Part 1
Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of \>=30,50,70,90,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by \>=30%.Variables included: number of joints with active arthritis(any joint with swelling, or absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on VAS from 0=no disease activity to 10=very severe disease activity, higher scores: greater disease activity; parent/legal guardian/child evaluation of overall well-being on VAS from 0=very well to 10mm=very poor, higher scores: worsen condition; functional ability (Disability Index ranged from 0=no or minimal physical dysfunction, 3=very severe physical dysfunction, higher scores: more physical dysfunction; ESR (mm/hr).
Time frame: Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12, and 16
Percentage of Participants With Adapted JIA ACR 30/50/70/90/100 Response at Part 2 Weeks 4, 8, 12, 16, 20 and 24: Open-label Phase Part 2
Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of \>=30,50,70,90,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by \>=30%.Variables included: number of joints with active arthritis(any joint with swelling, or absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on VAS from 0=no disease activity to 10=very severe disease activity, higher scores: greater disease activity; parent/legal guardian/child evaluation of overall well-being on VAS from 0=very well to 10mm=very poor, higher scores: worsen condition; functional ability (Disability Index ranged from 0=no or minimal physical dysfunction, 3=very severe physical dysfunction, higher scores: more physical dysfunction; ESR (mm/hr).
Time frame: Part 2 Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants With Fever Attributed to sJIA at Part 1 Days 3, 7 and 14: Open-Label Phase Part 1
Fever was defined as an oral temperature of ˃38 degree Celsius/100.4 degree Fahrenheit. 95% CI was based on normal approximation.
Time frame: Part 1 Days 3, 7 and 14
Percentage of Participants With C-Reactive Protein (CRP) <= 10 mg/L at Baseline, Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
Percentage of participants with CRP \<= 10 milligrams per liter (mg/L) along with 95% CI based on normal approximation is reported in this outcome.
Time frame: Baseline (last value collected prior to Day 1 of study treatment), Part 1 Days 3, 7, Part 1 Weeks 2, 4, 8, 12, 16
Percentage of Participants With C-Reactive Protein (CRP) <= 10 mg/L at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-label Phase Part 2
Percentage of participants with CRP \<= 10 mg/L along with 95% CI based on normal approximation is reported in this outcome.
Time frame: Part 2 Weeks 4, 8, 12, 16, 20, 24
Percentage of Participants With Absence of Fever Due to sJIA at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1
Percentage of participants with absence of fever along with 95% CI based on normal approximation is reported in this outcome.
Time frame: Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12, 16
Percentage of Participants With Absence of Fever Due to sJIA at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Percentage of participants with absence of fever along with 95% CI based on normal approximation is reported in this outcome.
Time frame: Part 2 Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants With Absence of Fever Due to sJIA at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double Blind Phase
Percentage of participants with absence of fever due sJIA is reported in this outcome. Missing response was imputed as non-response.
Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Time to First Adapted JIA ACR 30 Response: Open-label Phase Part 1
Time to the first adapted JIA ACR 30 response was measured in number of days since Day 1 (day of adapted JIA ACR 30 response - Day 1 + 1) in the OL Phase Part 1. Participants that did not achieve an adapted JIA ACR30 response defined as absence of fever due to sJIA \[temperature =\<38 degree Celsius/100.4 degree F in the preceding 7 days along with an improvement of at least 30% from baseline (Day 1 of study drug before first tofacitinib administration) in at least 3 of the 6 JIA core components, with worsening of \>=30 in no more than 1 of the remaining components, which in Part 1 (withdrew from the study) were censored at their last available response assessment in Part 1. 95% CI was based on the Brookmeyer and Crowley Method.
Time frame: From Day 1 up to 16 weeks
Change From Open Label Baseline in Juvenile Arthritis Disease Activity Score (JADAS-27) Erythrocyte Sedimentation Rate (ESR) at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) assessed on a VAS of 0 \[very well\] to 10 \[very poor\], ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16
Change From Open-Label Baseline in JADAS-27 CRP at Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16
Change From Open-Label Baseline in JADAS-27 ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20 and 24
Change From Open-Label Baseline in JADAS-27 CRP at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20 and 24
Change From Double-Blind Baseline in JADAS-27 ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: DB Baseline (at randomization on Day 1 in DB phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Double-Blind Baseline in JADAS-27 CRP at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
Time frame: DB Baseline (at randomization on Day 1 in DB phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Open-Label Baseline in Number of Joints With Active Arthritis at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16
Change From Open-Label Baseline in Number of Joints With Active Arthritis at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
Change From Open-Label Baseline in Number of Joints With Limited Range of Motion at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16
Change From Open-Label Baseline in Number of Joints With Limited Range of Motion at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), Toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-label Phase Part 1
Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10= maximum disease activity. Where higher scores indicated more disease activity.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16
Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10= maximum disease activity. Where higher scores indicated more disease activity.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
Change From Open-Label Baseline in ESR at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
ESR was determined using an ESR testing kit.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16
Change From Open-Label Baseline in ESR at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
ESR was determined using an ESR testing kit.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
Change From Open-Label Baseline in CHAQ- Parental Evaluation of Overall Well-being at Part 1 Days 3, 7, Part 1 Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0= very well and 10=very poorly. Where higher scores indicated worse condition.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Days 3,7, Part 1 Weeks 2, 4, 8, 12, 16
Change From Open-Label Baseline in CHAQ - Parental Evaluation of Overall Well-being at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0=Very Well and 10=Very Poorly. Where higher scores indicated worse condition.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
Change From Open-Label Baseline in CHAQ - Disability Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall Well-being. CHAQ disability index consisted of 30 items in 8 areas: 1. dressing and grooming, 2. arising, 3. eating, 4. walking, 5. hygiene, 6. reach, 7. grip, and 8. activities distributed. Each item was rated on a 4-point scale, scored from 0 (no difficulty) to 3 (unable to do). The eight areas of the CHAQ were averaged to calculate the total disability index score which ranged from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher scores indicated more disability. A participant must have score for at least six of the eight areas, otherwise a CHAQ-DI score was not valid.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 1 Day 7, Weeks 2, 4, 8, 12, 16
Change From Open-Label Baseline in CHAQ-Disability Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. CHAQ disability index consisted of 30 items in 8 areas, 1. dressing and grooming, 2. arising, 3. eating, 4. walking, 5. hygiene, 6. reach, 7. grip, and 8. activities distributed. Each item was rated on a 4-point scale, scored from 0 (no difficulty) to-3 (unable to do). The eight areas of the CHAQ were averaged to calculate the total disability index score which ranged from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher scores indicated more disability. A participant must have score for at least six of the eight areas, otherwise a CHAQ-DI score was not valid.
Time frame: Baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), Part 2 Weeks 4, 8, 12, 16, 20, 24
Change From Open-Label Baseline in Number of Joints With Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.
Time frame: OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Double-Blind Baseline in Number of Joints With Active Arthritis at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.
Time frame: DB Baseline (randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Open-Label Baseline in CHAQ-Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
The parents were asked to provide responses to questions designed to assessed function in 8 distributed, among a total of 30 items. Each question was rated on a four-point scale, scored from 0-3. The question with the highest score determined the score for the functional area. If aids or devices were used or assistance was required, the minimum score for that was 2. Each question was rated 0 for no difficulty, 1 for some difficulties, 2 for much difficulties, and 3 for unable to do. The 8 areas of the CHAQ were averaged to calculated disability index which was ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction). A participant must have score for at least 6 of the 8 categories, otherwise a CHAQ-DI score was not valid.
Time frame: OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Double Blind Baseline in CHAQ-Disability Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
The parents were asked to provide responses to questions designed to assessed function in 8 distributed, among a total of 30 items. Each question was rated on a four-point scale, scored from 0-3. The question with the highest score determined the score for the functional area. If aids or devices were used or assistance was required, the minimum score for that was 2. Each question was rated 0 for no difficulty, 1 for some difficulties, 2 for much difficulties, and 3 for unable to do. The 8 areas of the CHAQ were averaged to calculated disability index which was ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction). A participant must have score for at least 6 of the 8 categories, otherwise a CHAQ-DI score was not valid.
Time frame: DB Baseline (randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Open-Label Baseline in Number of Joints With Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.
Time frame: OL baseline (last value collected prior to day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Double-Blind Baseline in Number of Joints With Limited Range of Motion at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.
Time frame: DB Baseline (values at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Open-Label Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10=maximum disease activity, where higher scores indicated more disease activity.
Time frame: OL label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Double-Blind Baseline in Physician Global Evaluation of Disease Activity at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10=maximum disease activity, where higher scores indicated more disease activity.
Time frame: DB label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Open-Label Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
ESR was determined using an ESR testing kit.
Time frame: OL Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Double-Blind Baseline in ESR at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
ESR was determined using an ESR testing kit.
Time frame: DB Baseline (values at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Open-Label Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0'= very well' and '10= very poorly, where higher scores indicated worse condition.
Time frame: OL label Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Double-Blind Baseline in CHAQ -Parental Evaluation of Overall Well-being at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0'= very well' and '10=very poorly.
Time frame: DB Baseline (value at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change From Open-Label Baseline in Child Health Questionnaire (CHQ) Responses at End of Open-Label Phase Part 1
The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions (global health perception), physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4-6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. Range on subscales and the overall scale is 0 to 100, where 0 is the worst possible health state and 100 the best possible health state.
Time frame: OL Baseline up to 16 weeks
Change From Open-Label Baseline in CHQ Responses at End of Open-Label Phase Part 2
The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions (global health perception), physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4-6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. Range on subscales and the overall scale is 0 to 100, where 0 is the worst possible health state and 100 the best possible health state.
Time frame: Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) up to 24 weeks
Change From Double-Blind Baseline in CHQ Responses at DB Weeks 24, 48: Double-Blind Phase
The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions (global health perception), physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4-6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. Range on subscales and the overall scale is 0 to 100, where 0 is the worst possible health state and 100 the best possible health state.
Time frame: DB Baseline (values at randomization), DB Weeks 24, 48
Change From Open-Label Baseline in CHAQ-Discomfort Index at Part 1 Day 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'no pain' and '10' as 'very severe pain' on a 21-circle VAS, where higher scores indicated more severe pain.
Time frame: Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 1 Day 7, Weeks 2, 4, 8, 12, 16
Change From Open-label Baseline in CHAQ-Discomfort Index at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'no pain' and '10' as 'very severe pain' on a 21-circle VAS, where higher scores indicated more pain.
Time frame: Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 2 Weeks 4, 8, 12, 16, 20, 24
Change From Double-Blind Baseline in CHAQ-Discomfort Index at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'no pain' and '10' as 'very severe pain' on a 21-circle VAS, where higher scores indicated more severe pain.
Time frame: DB Baseline (value at randomization), DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of \<=2.
Time frame: Part 1 Day 7, Part 1 Weeks 2, 4, 8, 12 and 16
Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of \<=2.
Time frame: Part 1 Day 7, Weeks 2, 4, 8, 12 and 16
Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of \<=2.
Time frame: Part 2 Weeks 4, 8, 12, 16, 20, 24
Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of \<=2.
Time frame: Part 2 Weeks 4, 8, 12, 16, 20, 24
Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-label Phase Part 1
JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores:more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27,where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57,where higher scores:more disease activity.Inactive disease activity based on JADAS-27 CRP score was defined as: For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of:\<=1.For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of \<=1.
Time frame: Part 1 Day 7, Weeks 2, 4, 8, 12 and 16
Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 1 Day 7, Weeks 2, 4, 8, 12 and 16: Open-Label Phase Part 1
JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores:more inflammation and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive Disease activity based on JADAS-27 ESR score was defined as for participants with polyarthritis(\>4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of:\<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of \<=1.
Time frame: Part 1 Day 7, Weeks 2, 4, 8, 12 and 16
Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
JADAS-27 is a validated composite disease activity measure for JIA.Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores: more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27,where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57,where higher scores: more disease activity.Inactive disease activity based on JADAS-27 CRP score was defined as: For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of:\<=1.For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of \<=1.
Time frame: Part 2 Weeks 4, 8, 12, 16, 20, 24
Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores:more inflammation and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive Disease activity based on JADAS-27 ESR score was defined as for participants with polyarthritis(\>4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of:\<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of \<=1.
Time frame: Part 2 Weeks 4, 8, 12, 16, 20, 24
Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of \<=2.
Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Percentage of Participants With Minimum Disease Activity Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of \<=2.
Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 CRP Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-blind Phase
JADAS-27 is a validated composite disease activity measure for JIA.Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor),CRP (value normalized to 0 to 10 scale, where higher scores:more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity).The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive disease activity based on JADAS-27 CRP score was defined as: For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of:\<=1.For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of \<=1.
Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Percentage of Participants With Inactive Disease Status Calculated From JADAS-27 ESR Score at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores:more inflammation and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive Disease activity based on JADAS-27 ESR score was defined as for participants with polyarthritis(\>4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of:\<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of \<=1.
Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Percentage of Participants With JIA ACR Inactive Disease Status at Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16: Open-Label Phase Part 1
The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the 21-numbered circle VAS scale used (VAS from 0 to 10), higher scores indicated more disease activity; duration of morning stiffness of \<=15 minutes. 95% CI was based on normal approximation.
Time frame: Baseline (last value collected prior to Day 1 of tofacitinib administration in OL phase) Part 1 Days 3, 7, Weeks 2, 4, 8, 12, 16
Percentage of Participants With JIA ACR Inactive Disease Status at Part 2 Weeks 4, 8, 12, 16, 20, 24: Open-Label Phase Part 2
The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the 21-numbered circle VAS scale used (VAS from 0 to 10), higher scores indicated more disease activity; duration of morning stiffness of \<=15 minutes. 95% CI was based on normal approximation. 95% CI was based on normal approximation.
Time frame: Part 2 Weeks 4, 8, 12, 16, 20, 24
Percentage of Participants With JIA ACR Inactive Disease Status at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52: Double-Blind Phase
The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the 21-numbered circle VAS scale used (VAS from 0 to 10), higher scores indicated more disease activity; duration of morning stiffness of \<=15 minutes. 95% CI was based on normal approximation. 95% CI was based on normal approximation.
Time frame: DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Participants who were diagnosed with Systemic Juvenile Idiopathic Arthritis (sJIA) with active systemic features were enrolled.
| Milestone | Tofacitinib 5mg BID Open-Label (OL) Part 1 | Tofacitinib 5mg BID OL Part 2 | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|---|---|
| Started | 100 | 0 | 0 | 0 |
| Completed | 76 | 0 | 0 | 0 |
| Not completed | 24 | 0 | 0 | 0 |
| Withdrew: Adverse event | 6 | 0 | 0 | 0 |
| Withdrew: Other | 2 | 0 | 0 | 0 |
| Withdrew: Insufficient clinical response | 16 | 0 | 0 | 0 |
| Milestone | Tofacitinib 5mg BID Open-Label (OL) Part 1 | Tofacitinib 5mg BID OL Part 2 | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|---|---|
| Started | 0 | 54 | 0 | 0 |
| Completed | 0 | 37 | 0 | 0 |
| Not completed | 0 | 17 | 0 | 0 |
| Withdrew: Other | 0 | 5 | 0 | 0 |
| Withdrew: Insufficient clinical response | 0 | 12 | 0 | 0 |
| Milestone | Tofacitinib 5mg BID Open-Label (OL) Part 1 | Tofacitinib 5mg BID OL Part 2 | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|---|---|
| Started | 0 | 0 | 28 | 31 |
| Completed | 0 | 0 | 14 | 17 |
| Not completed | 0 | 0 | 14 | 14 |
| Withdrew: Adverse event | 0 | 0 | 2 | 1 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 2 | 0 |
| Withdrew: Other | 0 | 0 | 10 | 11 |
| Withdrew: Insufficient clinical response | 0 | 0 | 0 | 2 |
Time to the disease flare=the number of days from randomization to flare in the DB phase and calculated as date of disease flare minus (-) date of randomization plus (+) 1. sJIA Flare=as at least one of the following criteria: Recurrence of fever \>38 degree Celsius (C)/100.4 degree Fahrenheit (F) on 2 or more consecutive days) was considered due to SJIA activity. Worsening of 30 percent (%) or more in three or more of the six variables included: Number of joints with active arthritis and limited range of motion, disease activity, parent child evaluation of overall well-being, functional ability, childhood health assessment questionnaire ( CHAQ disability index), erythrocyte sedimentation rate (ESR) millimeter/ hour (mm/hr), of the JIA core set with no more than one variable of the JIA core set improving by 30% compared to the day of randomization into the withdrawal phase. 95% Confidence Interval (CI) based on Brookmeyer and Crowley Method.
| Days | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| Time to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind Phase | NA (186.0 to NA) | 295.0 (99.0 to NA) |
sJIA Flare was defined as at least one of the following criteria: recurrence of fever (\>38° C/100.4 degree F) on 2 or more consecutive days) was considered due to SJIA activity. Worsening of 30% or more in three or more of the six variables: number of joints with active arthritis and limited range of motion, disease activity, parent child evaluation of overall well-being, functional ability (CHAQ Disability Index), ESR. of the JIA core set with no more than one variable of the JIA core set improving by 30% compared to the day of randomization into the withdrawal phase. Probability of occurrence of sJIA disease flare with 95% CI were estimated using Kaplan-Meier method and reported in this outcome measure.
| Percentage probability of occurrence | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 7.1 | 6.5 |
| DB Week 8 | 14.3 | 22.6 |
| DB Week 12 | 21.4 | 32.3 |
| DB Week 16 | 25.0 | 38.7 |
| DB Week 20 | 32.1 | 45.4 |
| DB Week 24 | 32.1 | 45.4 |
| DB Week 28 | 35.9 | 45.4 |
| DB Week 32 | 35.9 | 49.9 |
| DB Week 36 | 40.5 | 49.9 |
| DB Week 40 | 40.5 | 49.9 |
| DB Week 44 | 40.5 | 55.5 |
| DB Week 48 | 40.5 | 55.5 |
| DB Week 52 | 40.5 | 55.5 |
A successfully tapered participant was considered as the one that completed part 2 of the OL by reaching their target corticosteroid dose and maintained an adapted JIA American College of Rheumatology (ACR) 30 response for four weeks on this dose. The target CS dose at the end of part 2 included less than equal to (\<=) 0.5 milligram/kilogram/day (mg/kg/day) up to a maximum dose of 15 milligram/ day (mg/day) oral prednisone (or equivalent) for CS\>0.8 mg/kg/day oral prednisone; reduction to \<=0.3 mg/kg/day up to a maximum of 12 mg/day oral prednisone (or equivalent) for CS \<=0.8 mg/kg/day to greater than equal to (\>=) 0.5 mg/kg/day oral prednisone (or equivalent) and \<=0.2 mg/kg/day up to a maximum dose of 10 mg/day oral prednisone (or equivalent) for CS \<0.5 mg/kg/day-CS˃0.2 mg/kg/day oral prednisone (or equivalent). 95% CI was based on normal approximation.
| Percentage of participants | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Percentage of Participants Who Achieved Successful Corticosteroid Tapering: at the End of Open-label Phase Part 2 | 70.37 (58.19 to 82.55) |
95% CI was based on normal approximation.
| Percentage of participants | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Percentage of Participants Who Achieved Corticosteroid Dose of <= 0.2 mg/kg/Day or 10 mg/Day: at the End of Open-label Phase Part 2 | 59.26 (46.15 to 72.36) |
Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of \>=30,50,70,90,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by \>=30%.Variables included: number of joints with active arthritis(any joint with swelling, or absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on VAS from 0=no disease activity to 10=very severe disease activity, higher scores:greater disease activity; parent/legal guardian/child evaluation of overall well-being on VAS from 0=very well to 10mm=very poor, higher scores: worsen condition; functional ability (Disability Index ranged from 0=no or minimal physical dysfunction, 3=very severe physical dysfunction, higher scores:more physical dysfunction;ESR (mm/hr).Missing response was imputed as non-response.
| Percentage of participants | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| ACR30:DB Week 4 | 82.14 (67.96 to 96.33) | 93.55 (84.90 to 100) |
| ACR30:DB Week 8 | 82.14 (67.96 to 96.33) | 80.65 (66.74 to 94.55) |
| ACR30:DB Week 12 | 71.43 (54.70 to 88.16) | 70.97 (54.99 to 86.95) |
| ACR30:DB Week 16 | 71.43 (54.70 to 88.16) | 61.29 (44.14 to 78.44) |
| ACR30:DB Week 20 | 67.86 (50.56 to 85.16) | 51.61 (34.02 to 69.21) |
| ACR30:DB Week 24 | 64.29 (46.54 to 82.03) | 54.84 (37.32 to 72.36) |
| ACR30:DB Week 28 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| ACR30:DB Week 32 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| ACR30:DB Week 36 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| ACR30:DB Week 40 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| ACR30:DB Week 44 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| ACR30:DB Week 48 | 60.71 (42.62 to 78.80) | 48.39 (30.79 to 65.98) |
| ACR30:DB Week 52 | 60.71 (42.62 to 78.80) | 48.39 (30.79 to 65.98) |
| ACR50:DB Week 4 | 82.14 (67.96 to 96.33) | 93.55 (84.90 to 100) |
| ACR50:DB Week 8 | 82.14 (67.96 to 96.33) | 77.42 (62.70 to 92.14) |
| ACR50:DB Week 12 | 71.43 (54.70 to 88.16) | 70.97 (54.99 to 86.95) |
| ACR50:DB Week 16 | 71.43 (54.70 to 88.16) | 58.06 (40.69 to 75.44) |
| ACR50:DB Week 20 | 67.86 (50.56 to 85.16) | 48.39 (30.79 to 65.98) |
| ACR50:DB Week 24 | 64.29 (46.54 to 82.03) | 54.84 (37.32 to 72.36) |
| ACR50:DB Week 28 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| ACR50:DB Week 32 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| ACR50:DB Week 36 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| ACR50:DB Week 40 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| ACR50:DB Week 44 | 60.71 (42.62 to 78.80) | 48.39 (30.79 to 65.98) |
| ACR50:DB Week 48 | 60.71 (42.62 to 78.80) | 48.39 (30.79 to 65.98) |
| ACR50:DB Week 52 | 60.71 (42.62 to 78.80) | 48.39 (30.79 to 65.98) |
| ACR70:DB Week 4 | 57.14 (38.81 to 75.47) | 70.97 (54.99 to 86.95) |
| ACR70:DB Week 8 | 67.86 (50.56 to 85.16) | 77.42 (62.70 to 92.14) |
| ACR70:DB Week 12 | 64.29 (46.54 to 82.03) | 64.52 (47.67 to 81.36) |
| ACR70:DB Week 16 | 60.71 (42.62 to 78.80) | 54.84 (37.32 to 72.36) |
| ACR70:DB Week 20 | 64.29 (46.54 to 82.03) | 45.16 (27.64 to 62.68) |
| ACR70:DB Week 24 | 53.57 (35.10 to 72.04) | 51.61 (34.02 to 69.21) |
| ACR70:DB Week 28 | 57.14 (38.81 to 75.47) | 41.94 (24.56 to 59.31) |
| ACR70:DB Week 32 | 60.71 (42.62 to 78.80) | 48.39 (30.79 to 65.98) |
| ACR70:DB Week 36 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| ACR70:DB Week 40 | 60.71 (42.62 to 78.80) | 48.39 (30.79 to 65.98) |
| ACR70:DB Week 44 | 60.71 (42.62 to 78.80) | 48.39 (30.79 to 65.98) |
| ACR70:DB Week 48 | 60.71 (42.62 to 78.80) | 48.39 (30.79 to 65.98) |
| ACR70:DB Week 52 | 60.71 (42.62 to 78.80) | 48.39 (30.79 to 65.98) |
| ACR90:DB Week 4 | 28.57 (11.84 to 45.30) | 48.39 (30.79 to 65.98) |
| ACR90:DB Week 8 | 21.43 (6.23 to 36.63) | 38.71 (21.56 to 55.86) |
| ACR90:DB Week 12 | 25.00 (8.96 to 41.04) | 38.71 (21.56 to 55.86) |
| ACR90:DB Week 16 | 25.00 (8.96 to 41.04) | 29.03 (13.05 to 45.01) |
| ACR90:DB Week 20 | 21.43 (6.23 to 36.63) | 29.03 (13.05 to 45.01) |
| ACR90:DB Week 24 | 21.43 (6.23 to 36.63) | 25.81 (10.40 to 41.21) |
| ACR90:DB Week 28 | 17.86 (3.67 to 32.04) | 25.81 (10.40 to 41.21) |
| ACR90:DB Week 32 | 14.29 (1.32 to 27.25) | 29.03 (13.05 to 45.01) |
| ACR90:DB Week 36 | 28.57 (11.84 to 45.30) | 35.48 (18.64 to 52.33) |
| ACR90:DB Week 40 | 28.57 (11.84 to 45.30) | 32.26 (15.80 to 48.71) |
| ACR90:DB Week 44 | 28.57 (11.84 to 45.30) | 29.03 (13.05 to 45.01) |
| ACR90:DB Week 48 | 28.57 (11.84 to 45.30) | 29.03 (13.05 to 45.01) |
| ACR90:DB Week 52 | 28.57 (11.84 to 45.30) | 29.03 (13.05 to 45.01) |
| ACR100:DB Week 4 | 14.29 (1.32 to 27.25) | 35.48 (18.64 to 52.33) |
| ACR100:DB Week 8 | 10.71 (0 to 22.17) | 29.03 (13.05 to 45.01) |
| ACR100:DB Week 12 | 14.29 (1.32 to 27.25) | 25.81 (10.40 to 41.21) |
| ACR100:DB Week 16 | 17.86 (3.67 to 32.04) | 25.81 (10.40 to 41.21) |
| ACR100:DB Week 20 | 14.29 (1.32 to 27.25) | 12.90 (1.10 to 24.70) |
| ACR100:DB Week 24 | 17.86 (3.67 to 32.04) | 19.35 (5.45 to 33.26) |
| ACR100:DB Week 28 | 14.29 (1.32 to 27.25) | 22.58 (7.86 to 37.30) |
| ACR100:DB Week 32 | 10.71 (0 to 22.17) | 25.81 (10.40 to 41.21) |
| ACR100:DB Week 36 | 14.29 (1.32 to 27.25) | 25.81 (10.40 to 41.21) |
| ACR100:DB Week 40 | 21.43 (6.23 to 36.63) | 29.03 (13.05 to 45.01) |
| ACR100:DB Week 44 | 21.43 (6.23 to 36.63) | 25.81 (10.40 to 41.21) |
| ACR100:DB Week 48 | 25.00 (8.96 to 41.04) | 25.81 (10.40 to 41.21) |
| ACR100:DB Week 52 | 25.00 (8.96 to 41.04) | 25.81 (10.40 to 41.21) |
Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of \>=30,50,70,90,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by \>=30%.Variables included: number of joints with active arthritis(any joint with swelling, or absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on VAS from 0=no disease activity to 10=very severe disease activity, higher scores: greater disease activity; parent/legal guardian/child evaluation of overall well-being on VAS from 0=very well to 10mm=very poor, higher scores: worsen condition; functional ability (Disability Index ranged from 0=no or minimal physical dysfunction, 3=very severe physical dysfunction, higher scores: more physical dysfunction; ESR (mm/hr).
| Percentage of participants | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| ACR30: Part 1 Day 7 | 26.26 (17.59 to 34.93) |
| ACR30: Part 1 Week 2 | 42.42 (32.69 to 52.16) |
| ACR30: Part 1 Week 4 | 68.04 (58.76 to 77.32) |
| ACR30: Part 1 Week 8 | 86.59 (79.21 to 93.96) |
| ACR30:Part 1 Week 12 | 90.91 (82.41 to 99.40) |
| ACR30: Part 1 Week 16 | 83.33 (68.42 to 98.24) |
| ACR50:Part 1 Day 7 | 18.18 (10.58 to 25.78) |
| ACR50:Part 1 Week 2 | 28.28 (19.41 to 37.15) |
| ACR50:Part 1 Week 4 | 44.33 (34.44 to 54.22) |
| ACR50:Part 1 Week 8 | 59.04 (48.46 to 69.62) |
| ACR50:Part 1 Week 12 | 79.55 (67.63 to 91.46) |
| ACR50:Part 1 Week 16 | 75.00 (57.68 to 92.32) |
| ACR70:Part 1 Day 7 | 10.10 (4.16 to 16.04) |
| ACR70:Part 1 Week 2 | 16.16 (8.91 to 23.41) |
| ACR70:Part 1 Week 4 | 19.59 (11.69 to 27.49) |
| ACR70:Part 1 Week 8 | 34.15 (23.88 to 44.41) |
| ACR70:Part 1 Week 12 | 38.64 (24.25 to 53.02) |
| ACR70:Part 1 Week 16 | 33.33 (14.47 to 52.19) |
| ACR90:Part 1 Day 7 | 5.05 (0.74 to 9.36) |
| ACR90:Part 1 Week 2 | 6.06 (1.36 to 10.76) |
| ACR90:Part 1 Week 4 | 11.34 (5.03 to 17.65) |
| ACR90:Part 1 Week 8 | 18.29 (9.92 to 26.66) |
| ACR90:Part 1 Week 12 | 15.91 (5.10 to 26.72) |
| ACR90:Part 1 Week 16 | 16.67 (1.76 to 31.58) |
| ACR100:Part 1 Day 7 | 3.03 (0 to 6.41) |
| ACR100:Part 1 Week 2 | 5.05 (0.74 to 9.36) |
| ACR100:Part 1 Week 4 | 8.25 (2.77 to 13.72) |
| ACR100:Part 1 Week 8 | 13.41 (6.04 to 20.79) |
| ACR100:Part 1 Week 12 | 9.09 (0.60 to 17.59) |
| ACR100:Part 1 Week 16 | 8.33 (0 to 19.39) |
Adapted JIA ACR 30,50,70,90,100 response=absence of fever due to sJIA in preceding 7 days along with improvement of \>=30,50,70,90,100%, respectively in at least 3 out of 6 JIA core set variables with no more than 1 JIA core set variable worsening by \>=30%.Variables included: number of joints with active arthritis(any joint with swelling, or absence of swelling, limitation of motion accompanied by either pain on motion or tenderness);number of joints with limited range of motion; physician global evaluation of disease activity on VAS from 0=no disease activity to 10=very severe disease activity, higher scores: greater disease activity; parent/legal guardian/child evaluation of overall well-being on VAS from 0=very well to 10mm=very poor, higher scores: worsen condition; functional ability (Disability Index ranged from 0=no or minimal physical dysfunction, 3=very severe physical dysfunction, higher scores: more physical dysfunction; ESR (mm/hr).
| Percentage of participants | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| ACR30:Part 2 Week 4 | 90.00 (81.68 to 98.32) |
| ACR30:Part 2 Week 8 | 87.50 (77.25 to 97.75) |
| ACR30:Part 2 Week 12 | 90.32 (79.91 to 100) |
| ACR30:Part 2 week 16 | 86.96 (73.19 to 100) |
| ACR30:Part 2 Week 20 | 100 (100 to 100) |
| ACR30:Part 2 Week 24 | 100 (100 to 100) |
| ACR50:Part 2 Week 4 | 86.00 (76.38 to 95.62) |
| ACR50:Part 2 Week 8 | 77.50 (64.56 to 90.44) |
| ACR50:Part 2 Week 12 | 80.65 (66.74 to 94.55) |
| ACR50:Part 2 Week 16 | 73.91 (55.97 to 91.86) |
| ACR50:Part 2 Week 20 | 92.31 (77.82 to 100) |
| ACR50:Part 2 Week 24 | 100 (100 to 100) |
| ACR70:Part 2 Week 4 | 68.00 (55.07 to 80.93) |
| ACR70:Part 2 Week 8 | 67.50 (52.98 to 82.02) |
| ACR70:Part 2 Week 12 | 70.97 (54.99 to 86.95) |
| ACR70:Part 2 Week 16 | 73.91 (55.97 to 91.86) |
| ACR70:Part 2 Week 20 | 92.31 (77.82 to 100) |
| ACR70:Part 2 Week 24 | 66.67 (13.32 to 100) |
| ACR90:Part 2 Week 4 | 32.00 (19.07 to 44.93) |
| ACR90:Part 2 Week 8 | 27.50 (13.66 to 41.34) |
| ACR90:Part 2 Week 12 | 22.58 (7.86 to 37.30) |
| ACR90:Part 2 Week 16 | 34.78 (15.32 to 54.25) |
| ACR90:Part 2 Week 20 | 53.85 (26.75 to 80.95) |
| ACR90:Part 2 Week 24 | 33.33 (0 to 86.68) |
| ACR100:Part 2 Week 4 | 28.00 (15.55 to 40.45) |
| ACR100:Part 2 Week 8 | 27.50 (13.66 to 41.34) |
| ACR100:Part 2 Week 12 | 16.13 (3.18 to 29.08) |
| ACR100:Part 2 Week 16 | 26.09 (8.14 to 44.03) |
| ACR100:Part 2 Week 20 | 38.46 (12.01 to 64.91) |
| ACR100:Part 2 Week 24 | 33.33 (0 to 86.68) |
Fever was defined as an oral temperature of ˃38 degree Celsius/100.4 degree Fahrenheit. 95% CI was based on normal approximation.
| Percentage of participants | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 3 | 3.13 (0 to 6.61) |
| Part 1 Day 7 | 1.03 (0 to 3.04) |
| Part 1 Day 14 | 4.12 (0.17 to 8.08) |
Percentage of participants with CRP \<= 10 milligrams per liter (mg/L) along with 95% CI based on normal approximation is reported in this outcome.
| Percentage of participants | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Baseline | 30.00 (21.02 to 38.98) |
| Part 1 Day 3 | 32.63 (23.20 to 42.06) |
| Part 1 Day 7 | 45.36 (35.45 to 55.27) |
| Part 1 Week 2 | 49.48 (39.53 to 59.43) |
| Part 1 Week 4 | 55.67 (45.78 to 65.56) |
| Part 1 Week 8 | 60.00 (49.26 to 70.74) |
| Part 1 Week 12 | 59.09 (44.56 to 73.62) |
| Part 1 Week 16 | 41.67 (21.94 to 61.39) |
Percentage of participants with CRP \<= 10 mg/L along with 95% CI based on normal approximation is reported in this outcome.
| Percentage of participants | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | 68.00 (55.07 to 80.93) |
| Part 2 Week 8 | 62.50 (47.50 to 77.50) |
| Part 2 Week 12 | 51.61 (34.02 to 69.21) |
| Part 2 Week 16 | 54.55 (33.74 to 75.35) |
| Part 2 Week 20 | 76.92 (54.02 to 99.83) |
| Part 2 Week 24 | 33.33 (0 to 86.68) |
Percentage of participants with absence of fever along with 95% CI based on normal approximation is reported in this outcome.
| Percentage of participants | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 7 | 83.51 (76.12 to 90.89) |
| Part 1 Week 2 | 82.47 (74.91 to 90.04) |
| Part 1 Week 4 | 90.72 (84.95 to 96.50) |
| Part 1 Week 8 | 96.39 (92.37 to 100) |
| Part 1 Week 12 | 100 (100 to 100) |
| Part 1 Week 16 | 95.83 (87.84 to 100) |
Percentage of participants with absence of fever along with 95% CI based on normal approximation is reported in this outcome.
| Percentage of participants | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | 98.00 (94.12 to 100) |
| Part 2 Week 8 | 92.31 (83.94 to 100) |
| Part 2 Week 12 | 96.77 (90.55 to 100) |
| Part 2 Week 16 | 90.91 (78.90 to 100) |
| Part 2 Week 20 | 100 (100 to 100) |
| Part 2 Week 24 | 100 (100 to 100) |
Percentage of participants with absence of fever due sJIA is reported in this outcome. Missing response was imputed as non-response.
| Percentage of participants | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 85.71 (72.75 to 98.68) | 93.55 (84.90 to 100) |
| DB Week 8 | 85.71 (72.75 to 98.68) | 80.65 (66.74 to 94.55) |
| DB Week 12 | 75.00 (58.96 to 91.04) | 74.19 (58.79 to 89.60) |
| DB Week 16 | 71.43 (54.70 to 88.16) | 61.29 (44.14 to 78.44) |
| DB Week 20 | 67.86 (50.56 to 85.16) | 51.61 (34.02 to 69.21) |
| DB Week 24 | 64.29 (46.54 to 82.03) | 54.84 (37.32 to 72.36) |
| DB Week 28 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| DB Week 32 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| DB Week 36 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| DB Week 40 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| DB Week 44 | 60.71 (42.62 to 78.80) | 51.61 (34.02 to 69.21) |
| DB Week 48 | 60.71 (42.62 to 78.80) | 48.39 (30.79 to 65.98) |
| DB Week 52 | 60.71 (42.62 to 78.80) | 48.39 (30.79 to 65.98) |
Time to the first adapted JIA ACR 30 response was measured in number of days since Day 1 (day of adapted JIA ACR 30 response - Day 1 + 1) in the OL Phase Part 1. Participants that did not achieve an adapted JIA ACR30 response defined as absence of fever due to sJIA \[temperature =\<38 degree Celsius/100.4 degree F in the preceding 7 days along with an improvement of at least 30% from baseline (Day 1 of study drug before first tofacitinib administration) in at least 3 of the 6 JIA core components, with worsening of \>=30 in no more than 1 of the remaining components, which in Part 1 (withdrew from the study) were censored at their last available response assessment in Part 1. 95% CI was based on the Brookmeyer and Crowley Method.
| Days | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Time to First Adapted JIA ACR 30 Response: Open-label Phase Part 1 | 27.0 (15.0 to 29.0) |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) assessed on a VAS of 0 \[very well\] to 10 \[very poor\], ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 7 | -5.64 ± 5.20 |
| Part 1 Week 2 | -8.57 ± 5.97 |
| Part 1 Week 4 | -11.95 ± 6.53 |
| Part 1 Week 8 | -15.09 ± 7.27 |
| Part 1 Week 12 | -15.77 ± 7.24 |
| Part 1 Week 16 | -14.08 ± 6.09 |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 7 | -6.25 ± 5.53 |
| Part 1 Week 2 | -8.55 ± 6.10 |
| Part 1 Week 4 | -11.88 ± 7.28 |
| Part 1 Week 8 | -15.07 ± 8.46 |
| Part 1 Week 12 | -15.19 ± 7.73 |
| Part 1 Week 16 | -13.10 ± 6.37 |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | -17.05 ± 8.18 |
| Part 2 Week 8 | -17.13 ± 8.14 |
| Part 2 Week 12 | -18.17 ± 7.74 |
| Part 2 Week 16 | -18.89 ± 7.56 |
| Part 2 Week 20 | -21.14 ± 5.78 |
| Part 2 Week 24 | -22.17 ± 7.58 |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | -17.16 ± 8.87 |
| Part 2 Week 8 | -17.44 ± 8.03 |
| Part 2 Week 12 | -18.99 ± 7.67 |
| Part 2 Week 16 | -20.31 ± 6.41 |
| Part 2 Week 20 | -22.16 ± 7.05 |
| Part 2 Week 24 | -25.61 ± 9.82 |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ) (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), ESR (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 1.07 ± 0.84 | 1.08 ± 0.79 |
| DB Week 8 | 1.75 ± 1.08 | 0.81 ± 1.06 |
| DB Week 12 | 1.47 ± 1.46 | 1.71 ± 1.40 |
| DB Week 16 | 0.43 ± 1.03 | 1.29 ± 1.04 |
| DB Week 20 | -1.04 ± 0.65 | 0.05 ± 0.69 |
| DB Week 24 | -0.49 ± 0.57 | -0.79 ± 0.60 |
| DB Week 28 | 2.58 ± 2.05 | 3.86 ± 2.25 |
| DB Week 32 | -0.21 ± 0.77 | -0.68 ± 0.83 |
| DB Week 36 | -1.52 ± 0.50 | -1.26 ± 0.54 |
| DB Week 40 | -0.23 ± 0.91 | -0.96 ± 0.96 |
| DB Week 44 | -1.67 ± 0.75 | -0.83 ± 0.79 |
| DB Week 48 | -2.29 ± 0.38 | -2.06 ± 0.60 |
| DB Week 52 | -2.41 ± 0.60 | -1.65 ± 1.07 |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), CRP (value normalized to 0 to 10 scale) and number of joints with active disease (27 joint assessment ranging from 0 to 27). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57. A higher score indicated more disease activity.
| Units on a scale | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 1.62 ± 0.96 | 0.71 ± 0.90 |
| DB Week 8 | 2.12 ± 0.95 | 0.01 ± 0.93 |
| DB Week 12 | 1.78 ± 1.46 | 1.80 ± 1.40 |
| DB Week 16 | 0.84 ± 1.09 | 1.95 ± 1.08 |
| DB Week 20 | -0.17 ± 0.84 | 0.36 ± 0.87 |
| DB Week 24 | 1.58 ± 1.04 | -0.26 ± 1.08 |
| DB Week 28 | 2.64 ± 1.86 | 2.72 ± 2.04 |
| DB Week 32 | 0.49 ± 0.99 | 1.18 ± 1.07 |
| DB Week 36 | -1.59 ± 0.50 | -1.24 ± 0.53 |
| DB Week 40 | 0.38 ± 1.15 | 0.41 ± 1.21 |
| DB Week 44 | -1.09 ± 0.99 | 1.50 ± 1.02 |
| DB Week 48 | -2.04 ± 0.51 | -1.23 ± 0.76 |
| DB Week 52 | -2.31 ± 0.60 | -1.85 ± 1.10 |
The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.
| Joints | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 7 | -2.96 ± 4.17 |
| Part 1 Week 2 | -4.21 ± 5.31 |
| Part 1 Week 4 | -6.03 ± 6.04 |
| Part 1 Week 8 | -7.80 ± 9.25 |
| Part 1 Week 12 | -7.52 ± 7.38 |
| Part 1 Week 16 | -6.38 ± 7.87 |
The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.
| Joints | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | -7.78 ± 7.78 |
| Part 2 Week 8 | -7.73 ± 8.40 |
| Part 2 Week 12 | -9.26 ± 7.98 |
| Part 2 Week 16 | -10.00 ± 7.99 |
| Part 2 Week 20 | -10.85 ± 7.83 |
| Part 2 Week 24 | -13.67 ± 11.02 |
Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.
| Joints | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 7 | -1.83 ± 4.26 |
| Part 1 Week 2 | -2.06 ± 4.70 |
| Part 1 Week 4 | -2.90 ± 5.42 |
| Part 1 Week 8 | -4.36 ± 8.59 |
| Part 1 Week 12 | -3.64 ± 6.05 |
| Part 1 Week 16 | -2.33 ± 3.48 |
Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), Toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.
| Joints | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | -4.26 ± 6.75 |
| Part 2 Week 8 | -3.90 ± 6.08 |
| Part 2 Week 12 | -5.81 ± 7.48 |
| Part 2 Week 16 | -5.74 ± 7.13 |
| Part 2 Week 20 | -5.92 ± 9.32 |
| Part 2 Week 24 | -15.67 ± 11.02 |
Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10= maximum disease activity. Where higher scores indicated more disease activity.
| units on a scale | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 7 | -1.18 ± 1.36 |
| Part 1 Week 2 | -1.82 ± 1.68 |
| Part 1 Week 4 | -2.62 ± 1.75 |
| Part 1 Week 8 | -3.40 ± 2.01 |
| Part 1 Week 12 | -3.66 ± 2.08 |
| Part 1 Week 16 | -3.50 ± 1.93 |
Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10= maximum disease activity. Where higher scores indicated more disease activity.
| Unit on a scale | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | -4.54 ± 2.10 |
| Part 2 Week 8 | -4.53 ± 1.74 |
| Part 2 Week 12 | -4.65 ± 1.57 |
| Part 2 Week 16 | -4.89 ± 1.77 |
| Part 2 Week 20 | -5.62 ± 1.21 |
| Part 2 Week 24 | -6.17 ± 1.44 |
ESR was determined using an ESR testing kit.
| Millimeter per hour | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 7 | -11.00 ± 16.96 |
| Part 1 Week 2 | -18.60 ± 19.78 |
| Part 1 Week 4 | -24.70 ± 23.86 |
| Part 1 Week 8 | -30.59 ± 23.12 |
| Part 1 Week 12 | -31.74 ± 21.75 |
| Part 1 Week 16 | -27.65 ± 28.84 |
ESR was determined using an ESR testing kit.
| Millimeter per hour | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | -33.64 ± 28.16 |
| Part 2 Week 8 | -30.73 ± 27.11 |
| Part 2 Week 12 | -27.52 ± 28.13 |
| Part 2 Week 16 | -23.48 ± 24.70 |
| Part 2 Week 20 | -37.54 ± 20.93 |
| Part 2 Week 24 | -24.33 ± 6.03 |
The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0= very well and 10=very poorly. Where higher scores indicated worse condition.
| Units on a scale | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 3 | -0.73 ± 1.53 |
| Part 1 Day 7 | -1.36 ± 1.91 |
| Part 1 Week 2 | -1.96 ± 1.89 |
| Part 1 Week 4 | -2.65 ± 2.44 |
| Part 1 Week 8 | -3.35 ± 2.38 |
| Part 1 Week 12 | -3.45 ± 2.45 |
| Part 1 Week 16 | -3.48 ± 2.78 |
The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0=Very Well and 10=Very Poorly. Where higher scores indicated worse condition.
| Units on a scale | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | -4.09 ± 2.68 |
| Part 2 Week 8 | -4.50 ± 2.88 |
| Part 2 Week 12 | -4.73 ± 2.83 |
| Part 2 Week 16 | -5.11 ± 2.50 |
| Part 2 Week 20 | -5.65 ± 2.89 |
| Part 2 Week 24 | -6.33 ± 2.31 |
CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall Well-being. CHAQ disability index consisted of 30 items in 8 areas: 1. dressing and grooming, 2. arising, 3. eating, 4. walking, 5. hygiene, 6. reach, 7. grip, and 8. activities distributed. Each item was rated on a 4-point scale, scored from 0 (no difficulty) to 3 (unable to do). The eight areas of the CHAQ were averaged to calculate the total disability index score which ranged from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher scores indicated more disability. A participant must have score for at least six of the eight areas, otherwise a CHAQ-DI score was not valid.
| Units on a scale | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 7 | -0.21 ± 0.35 |
| Part 1 Week 2 | -0.38 ± 0.43 |
| Part 1 Week 4 | -0.52 ± 0.56 |
| Part 1 Week 8 | -0.59 ± 0.57 |
| Part 1 Week 12 | -0.51 ± 0.56 |
| Part 1 Week 16 | -0.74 ± 0.73 |
CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. CHAQ disability index consisted of 30 items in 8 areas, 1. dressing and grooming, 2. arising, 3. eating, 4. walking, 5. hygiene, 6. reach, 7. grip, and 8. activities distributed. Each item was rated on a 4-point scale, scored from 0 (no difficulty) to-3 (unable to do). The eight areas of the CHAQ were averaged to calculate the total disability index score which ranged from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher scores indicated more disability. A participant must have score for at least six of the eight areas, otherwise a CHAQ-DI score was not valid.
| Units on a scale | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | -0.79 ± 0.63 |
| Part 2 Week 8 | -0.78 ± 0.76 |
| Part 2 Week 12 | -0.85 ± 0.80 |
| Part 2 Week 16 | -0.67 ± 0.74 |
| Part 2 Week 20 | -0.93 ± 0.77 |
| Part 2 Week 24 | -0.96 ± 0.92 |
The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.
| Joints | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | -6.53 ± 0.34 | -7.39 ± 0.32 |
| DB Week 8 | -6.36 ± 0.38 | -7.69 ± 0.38 |
| DB Week 12 | -5.92 ± 0.80 | -7.36 ± 0.76 |
| DB Week 16 | -7.34 ± 0.25 | -7.37 ± 0.25 |
| DB Week 20 | -7.41 ± 0.18 | -7.51 ± 0.20 |
| DB Week 24 | -7.33 ± 0.13 | -7.76 ± 0.13 |
| DB Week 28 | -6.36 ± 0.59 | -6.56 ± 0.67 |
| DB Week 32 | -7.27 ± 0.17 | -7.76 ± 0.19 |
| DB Week 36 | -7.43 ± 0.14 | -7.78 ± 0.16 |
| DB Week 40 | -7.06 ± 0.24 | -7.58 ± 0.27 |
| DB Week 44 | -7.39 ± 0.33 | -7.20 ± 0.35 |
| DB Week 48 | -7.54 ± 0.20 | -7.75 ± 0.25 |
| DB Week 52 | -7.46 ± 0.26 | -7.51 ± 0.28 |
The ACR defined a joint with active arthritis as a joint with swelling or, in the absence of swelling, limitation of motion accompanied by pain on motion, or tenderness.
| Joints | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 0.38 ± 0.26 | 0.09 ± 0.24 |
| DB Week 8 | 0.78 ± 0.38 | -0.23 ± 0.37 |
| DB Week 12 | 1.47 ± 0.85 | 0.22 ± 0.81 |
| DB Week 16 | 0.05 ± 0.27 | -0.05 ± 0.27 |
| DB Week 20 | -0.15 ± 0.15 | -0.02 ± 0.17 |
| DB Week 24 | -0.06 ± 0.12 | -0.39 ± 0.13 |
| DB Week 28 | 0.71 ± 0.70 | 0.88 ± 0.84 |
| DB Week 32 | 0.01 ± 0.18 | -0.41 ± 0.20 |
| DB Week 36 | -0.14 ± 0.15 | -0.47 ± 0.17 |
| DB Week 40 | 0.31 ± 0.25 | -0.37 ± 0.28 |
| DB Week 44 | -0.05 ± 0.35 | 0.11 ± 0.38 |
| DB Week 48 | -0.20 ± 0.21 | -0.56 ± 0.27 |
| DB Week 52 | -0.14 ± 0.28 | -0.38 ± 0.34 |
The parents were asked to provide responses to questions designed to assessed function in 8 distributed, among a total of 30 items. Each question was rated on a four-point scale, scored from 0-3. The question with the highest score determined the score for the functional area. If aids or devices were used or assistance was required, the minimum score for that was 2. Each question was rated 0 for no difficulty, 1 for some difficulties, 2 for much difficulties, and 3 for unable to do. The 8 areas of the CHAQ were averaged to calculated disability index which was ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction). A participant must have score for at least 6 of the 8 categories, otherwise a CHAQ-DI score was not valid.
| Units on a scale | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | -0.81 ± 0.10 | -1.03 ± 0.09 |
| DB Week 8 | -0.93 ± 0.08 | -1.02 ± 0.08 |
| DB Week 12 | -0.99 ± 0.08 | -1.04 ± 0.07 |
| DB Week 16 | -0.95 ± 0.09 | -1.05 ± 0.09 |
| DB Week 20 | -1.02 ± 0.07 | -1.21 ± 0.07 |
| DB Week 24 | -0.94 ± 0.08 | -1.05 ± 0.08 |
| DB Week 28 | -0.94 ± 0.08 | -1.01 ± 0.09 |
| DB Week 32 | -0.96 ± 0.07 | -1.11 ± 0.07 |
| DB Week 36 | -1.05 ± 0.08 | -1.16 ± 0.09 |
| DB Week 40 | -1.07 ± 0.07 | -1.22 ± 0.08 |
| DB Week 44 | -1.04 ± 0.09 | -1.08 ± 0.09 |
| DB Week 48 | -1.01 ± 0.09 | -1.10 ± 0.11 |
| DB Week 52 | -1.04 ± 0.10 | -1.13 ± 0.12 |
The parents were asked to provide responses to questions designed to assessed function in 8 distributed, among a total of 30 items. Each question was rated on a four-point scale, scored from 0-3. The question with the highest score determined the score for the functional area. If aids or devices were used or assistance was required, the minimum score for that was 2. Each question was rated 0 for no difficulty, 1 for some difficulties, 2 for much difficulties, and 3 for unable to do. The 8 areas of the CHAQ were averaged to calculated disability index which was ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction). A participant must have score for at least 6 of the 8 categories, otherwise a CHAQ-DI score was not valid.
| Units on a scale | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 0.04 ± 0.06 | -0.02 ± 0.06 |
| DB Week 8 | -0.03 ± 0.06 | -0.01 ± 0.06 |
| DB Week 12 | -0.06 ± 0.06 | -0.05 ± 0.06 |
| DB Week 16 | -0.03 ± 0.07 | -0.05 ± 0.07 |
| DB Week 20 | -0.08 ± 0.06 | -0.23 ± 0.06 |
| DB Week 24 | 0.06 ± 0.08 | -0.09 ± 0.08 |
| DB Week 28 | 0.05 ± 0.08 | -0.04 ± 0.09 |
| DB Week 32 | 0.02 ± 0.07 | -0.13 ± 0.07 |
| DB Week 36 | -0.03 ± 0.09 | -0.19 ± 0.09 |
| DB Week 40 | -0.09 ± 0.07 | -0.25 ± 0.07 |
| DB Week 44 | -0.06 ± 0.09 | -0.10 ± 0.09 |
| DB Week 48 | -0.03 ± 0.09 | -0.19 ± 0.12 |
| DB Week 52 | -0.05 ± 0.10 | -0.21 ± 0.13 |
Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.
| Joints | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | -2.47 ± 0.43 | -2.69 ± 0.41 |
| DB Week 8 | -2.31 ± 0.45 | -2.89 ± 0.44 |
| DB Week 12 | -2.09 ± 0.71 | -3.29 ± 0.68 |
| DB Week 16 | -2.76 ± 0.44 | -2.70 ± 0.43 |
| DB Week 20 | -2.79 ± 0.19 | -3.05 ± 0.19 |
| DB Week 24 | -2.98 ± 0.19 | -3.07 ± 0.19 |
| DB Week 28 | -2.56 ± 0.54 | -2.10 ± 0.56 |
| DB Week 32 | -2.89 ± 0.18 | -3.24 ± 0.19 |
| DB Week 36 | -2.90 ± 0.19 | -3.21 ± 0.21 |
| DB Week 40 | -2.96 ± 0.24 | -3.24 ± 0.25 |
| DB Week 44 | -2.95 ± 0.25 | -3.24 ± 0.26 |
| DB Week 48 | -3.03 ± 0.27 | -3.25 ± 0.30 |
| DB Week 52 | -2.75 ± 0.36 | -3.20 ± 0.36 |
Limitation of motion were assessed in the following joints: Temporomandibular, shoulder, elbow, wrist, metacarpophalangeal (MCP I-V), proximal interphalangeal (PIP I-V), distal interphalangeal (II-V), hip, knee, ankle, subtalar joints, intertarsal joints, metatarsophalangeal (MTP I-V), toe interphalangeal (I-V), cervical spine, thoracic spine, lumbar spine.
| Joints | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 0.08 ± 0.22 | 0.21 ± 0.20 |
| DB Week 8 | 0.45 ± 0.42 | 0.06 ± 0.42 |
| DB Week 12 | 0.48 ± 0.44 | -0.23 ± 0.42 |
| DB Week 16 | -0.30 ± 0.17 | 0.10 ± 0.17 |
| DB Week 20 | -0.36 ± 0.10 | -0.19 ± 0.11 |
| DB Week 24 | -0.53 ± 0.10 | -0.22 ± 0.11 |
| DB Week 28 | -0.05 ± 0.40 | 1.05 ± 0.46 |
| DB Week 32 | -0.41 ± 0.10 | -0.48 ± 0.12 |
| DB Week 36 | -0.48 ± 0.09 | -0.46 ± 0.10 |
| DB Week 40 | -0.48 ± 0.15 | -0.43 ± 0.17 |
| DB Week 44 | -0.47 ± 0.16 | -0.43 ± 0.17 |
| DB Week 48 | -0.50 ± 0.20 | -0.47 ± 0.24 |
| DB Week 52 | -0.21 ± 0.31 | -0.42 ± 0.33 |
Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10=maximum disease activity, where higher scores indicated more disease activity.
| Units on a scale | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | -4.22 ± 0.33 | -5.22 ± 0.32 |
| DB Week 8 | -4.23 ± 0.32 | -5.55 ± 0.32 |
| DB Week 12 | -4.89 ± 0.36 | -5.42 ± 0.34 |
| DB Week 16 | -4.96 ± 0.32 | -5.22 ± 0.32 |
| DB Week 20 | -5.32 ± 0.23 | -5.64 ± 0.24 |
| DB Week 24 | -5.11 ± 0.22 | -5.66 ± 0.23 |
| DB Week 28 | -5.06 ± 0.37 | -5.26 ± 0.40 |
| DB Week 32 | -5.08 ± 0.26 | -5.71 ± 0.28 |
| DB Week 36 | -5.55 ± 0.16 | -6.03 ± 0.18 |
| DB Week 40 | -5.23 ± 0.30 | -5.88 ± 0.33 |
| DB Week 44 | -5.65 ± 0.21 | -5.87 ± 0.22 |
| DB Week 48 | -5.87 ± 0.18 | -6.14 ± 0.24 |
| DB Week 52 | -5.86 ± 0.26 | -5.97 ± 0.33 |
Physician global evaluation of disease activity was assessed on a 21-numbered circle VAS ranging from 0 to 10, where 0= no disease activity and 10=maximum disease activity, where higher scores indicated more disease activity.
| Units on a scale | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 0.16 ± 0.25 | 0.21 ± 0.24 |
| DB Week 8 | 0.45 ± 0.32 | -0.14 ± 0.32 |
| DB Week 12 | 0.10 ± 0.40 | -0.02 ± 0.39 |
| DB Week 16 | -0.11 ± 0.34 | 0.15 ± 0.34 |
| DB Week 20 | -0.51 ± 0.22 | -0.35 ± 0.23 |
| DB Week 24 | -0.32 ± 0.22 | -0.37 ± 0.22 |
| DB Week 28 | 0.09 ± 0.43 | 0.19 ± 0.47 |
| DB Week 32 | -0.11 ± 0.29 | -0.42 ± 0.32 |
| DB Week 36 | -0.74 ± 0.17 | -0.92 ± 0.18 |
| DB Week 40 | -0.17 ± 0.35 | -0.53 ± 0.37 |
| DB Week 44 | -0.79 ± 0.21 | -0.70 ± 0.22 |
| DB Week 48 | -1.03 ± 0.20 | -1.09 ± 0.29 |
| DB Week 52 | -1.00 ± 0.27 | -0.92 ± 0.39 |
ESR was determined using an ESR testing kit.
| Millimeter per hour (mm/h) | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | -32.65 ± 4.72 | -31.19 ± 4.49 |
| DB Week 8 | -36.55 ± 4.38 | -29.32 ± 4.29 |
| DB Week 12 | -38.30 ± 4.50 | -31.69 ± 4.35 |
| DB Week 16 | -39.52 ± 4.06 | -31.02 ± 4.06 |
| DB Week 20 | -41.82 ± 2.22 | -37.86 ± 2.32 |
| DB Week 24 | -42.25 ± 2.25 | -40.81 ± 2.33 |
| DB Week 28 | -37.83 ± 4.07 | -33.51 ± 4.39 |
| DB Week 32 | -37.90 ± 3.67 | -35.04 ± 3.91 |
| DB Week 36 | -39.36 ± 4.49 | -28.41 ± 4.79 |
| DB Week 40 | -39.98 ± 4.12 | -35.70 ± 4.31 |
| DB Week 44 | -47.16 ± 2.28 | -38.84 ± 2.34 |
| DB Week 48 | -47.16 ± 2.29 | -42.32 ± 2.72 |
| DB Week 52 | -51.46 ± 1.08 | -50.12 ± 1.24 |
ESR was determined using an ESR testing kit.
| Millimeter/ hour (mm/h) | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 3.35 ± 3.71 | 9.41 ± 3.50 |
| DB Week 8 | 1.94 ± 3.97 | 12.39 ± 3.93 |
| DB Week 12 | 1.42 ± 4.53 | 12.28 ± 4.40 |
| DB Week 16 | 0.45 ± 4.32 | 13.59 ± 4.35 |
| DB Week 20 | -2.04 ± 2.17 | 4.98 ± 2.31 |
| DB Week 24 | -2.51 ± 2.14 | 2.01 ± 2.28 |
| DB Week 28 | 1.73 ± 4.19 | 11.08 ± 4.55 |
| DB Week 32 | 2.01 ± 3.78 | 8.77 ± 4.05 |
| DB Week 36 | 0.88 ± 4.83 | 16.37 ± 5.17 |
| DB Week 40 | 0.34 ± 4.25 | 8.33 ± 4.47 |
| DB Week 44 | -7.05 ± 2.34 | 3.44 ± 2.41 |
| DB Week 48 | -8.07 ± 2.38 | -2.14 ± 2.96 |
| DB Week 52 | -11.70 ± 1.39 | -9.14 ± 1.73 |
The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0'= very well' and '10= very poorly, where higher scores indicated worse condition.
| Units on a scale | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | -4.31 ± 0.37 | -5.52 ± 0.34 |
| DB Week 8 | -4.56 ± 0.36 | -5.38 ± 0.35 |
| DB Week 12 | -4.97 ± 0.34 | -5.28 ± 0.33 |
| DB Week 16 | -4.88 ± 0.29 | -5.46 ± 0.29 |
| DB Week 20 | -5.19 ± 0.32 | -5.36 ± 0.34 |
| DB Week 24 | -4.97 ± 0.29 | -5.62 ± 0.30 |
| DB Week 28 | -5.08 ± 0.44 | -5.00 ± 0.48 |
| DB Week 32 | -5.63 ± 0.18 | -5.55 ± 0.20 |
| DB Week 36 | -5.81 ± 0.18 | -5.87 ± 0.21 |
| DB Week 40 | -5.98 ± 0.16 | -5.94 ± 0.18 |
| DB Week 44 | -5.95 ± 0.21 | -5.79 ± 0.23 |
| DB Week 48 | -5.45 ± 0.31 | -5.30 ± 0.57 |
| DB Week 52 | -6.06 ± 0.25 | -5.98 ± 0.43 |
The CHAQ, derived from the adult health assessment questionnaire, comprised of two indices disability and discomfort, and parent global assessment of overall well-being. For assessment of overall well-being, the parent/legal guardian/participant were required to rate the overall well-being by entering a number from 0 to 10 (in 0.5 increments), on a 21-circle VAS where '0'= very well' and '10=very poorly.
| Units on a scale | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 0.46 ± 0.28 | -0.03 ± 0.27 |
| DB Week 8 | 0.60 ± 0.38 | 0.12 ± 0.38 |
| DB Week 12 | 0.25 ± 0.36 | 0.22 ± 0.35 |
| DB Week 16 | 0.27 ± 0.31 | 0.04 ± 0.31 |
| DB Week 20 | 0.14 ± 0.37 | 0.05 ± 0.38 |
| DB Week 24 | 0.14 ± 0.29 | -0.14 ± 0.30 |
| DB Week 28 | 0.54 ± 0.52 | 0.52 ± 0.56 |
| DB Week 32 | -0.32 ± 0.24 | -0.34 ± 0.25 |
| DB Week 36 | -0.56 ± 0.21 | -0.63 ± 0.22 |
| DB Week 40 | -0.72 ± 0.19 | -0.78 ± 0.20 |
| DB Week 44 | -0.65 ± 0.24 | -0.54 ± 0.25 |
| DB Week 48 | -0.16 ± 0.36 | -0.37 ± 0.53 |
| DB Week 52 | -0.82 ± 0.26 | -0.87 ± 0.38 |
The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions (global health perception), physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4-6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. Range on subscales and the overall scale is 0 to 100, where 0 is the worst possible health state and 100 the best possible health state.
| Units on a scale | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Global Health Subscale Standardized Score | 26.12 ± 29.10 |
| Physical Functioning Subscale Standardized Score | 28.95 ± 33.79 |
| Social Limitations: Emotional Subscale Standardized Score | 27.51 ± 38.39 |
| Social Limitations: Physical Subscale Standardized Score | 31.15 ± 42.96 |
| Bodily Pain Subscale Standardized Score | 32.00 ± 26.67 |
| Behavior Subscale Standardized Score | 10.98 ± 17.14 |
| Global Behavior Subscale Standardized Score | 11.18 ± 27.75 |
| Mental Health Subscale Standardized Score | 13.33 ± 20.20 |
| Self Esteem Subscale Standardized Score | 7.68 ± 21.29 |
| General Health Subscale Standardized Score | 8.37 ± 13.93 |
| Change in Health Subscale Score | 1.28 ± 1.10 |
| Emotional Impact on Parent Subscale Standardized Score | 12.75 ± 26.43 |
| Time Impact on Parent Subscale Standardized Score | 14.81 ± 28.62 |
| Family Activities Subscale Standardized Score | 74.03 ± 22.41 |
| Family Cohesion Subscale Standardized Score | 8.10 ± 22.67 |
The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions (global health perception), physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4-6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. Range on subscales and the overall scale is 0 to 100, where 0 is the worst possible health state and 100 the best possible health state.
| Units on a scale | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Global Health Standardized Score | 25.52 ± 35.46 |
| Physical Functioning Standardized Score | 33.33 ± 31.29 |
| Social Limitations: Emotional Score | 28.17 ± 43.98 |
| Social Limitations: Physical Score | 38.10 ± 42.28 |
| Bodily Pain Standardized Score | 34.48 ± 26.80 |
| Behavior Standardized Score | 13.02 ± 21.14 |
| Global Behavior Standardized Score | 10.00 ± 34.10 |
| Mental Health Standardized Score | 18.04 ± 21.01 |
| Self Esteem Standardized Score | 8.30 ± 34.18 |
| General Health Standardized Score | 8.18 ± 15.94 |
| Change in Health Subscale Score | 1.54 ± 1.23 |
| Emotional Impact on Parent Standardized Score | 22.92 ± 36.33 |
| Time Impact on Parent Standardized Score | 34.57 ± 25.66 |
| Family Activities Standardized Score | 27.62 ± 25.87 |
| Family Cohesion Standardized Score | 10.00 ± 23.25 |
The CHQ is a validated general pediatric quality of life instrument. The CHQ assessed for 14 physical and psychosocial domains: general health perceptions (global health perception), physical functioning, role/social physical functioning, bodily pain, role/social emotional functioning, role/social behavioral functioning, parent/legal guardian/adult caregiver impact-time, parent/legal guardian/adult caregiver impact-emotional, self-esteem, mental health, behavior, family activities, family cohesion, and change in health. The response options for the CHQ are ordinal scales that vary by the item. Each item consisted of 4-6 response options. The CHQ score was determined based on the parent/legal guardian/adult caregiver's questionnaire responses. Range on subscales and the overall scale is 0 to 100, where 0 is the worst possible health state and 100 the best possible health state.
| Units on a scale | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| CHQ01-Global Health Subscale Standardized Score: DB Week 24 | 4.02 ± 4.71 | -1.98 ± 5.02 |
| CHQ01-Global Health Subscale Standardized Score: DB Week 48 | 4.09 ± 3.93 | 1.24 ± 4.49 |
| CHQ01-Physical Functioning Subscale Standardized Score: DB Week 24 | 2.51 ± 3.86 | 6.70 ± 3.99 |
| CHQ01-Physical Functioning Subscale Standardized Score: DB Week 48 | 5.24 ± 9.13 | 2.93 ± 14.02 |
| CHQ01-Social Limitations: Emotional Subscale Standardized Score: DB Week 24 | 2.62 ± 4.00 | 8.09 ± 4.18 |
| CHQ01-Social Limitations: Emotional Subscale Standardized Score: DB Week 48 | 6.09 ± 7.69 | -0.73 ± 10.33 |
| CHQ01-Social Limitations: Physical Subscale Standardized Score: DB Week 24 | 2.75 ± 4.27 | 8.98 ± 4.54 |
| CHQ01-Social Limitations: Physical Subscale Standardized Score: DB Week 48 | 3.45 ± 13.33 | -7.64 ± 20.06 |
| CHQ01-Bodily Pain Subscale Standardized Score: DB Week 24 | -1.61 ± 4.19 | -0.16 ± 4.41 |
| CHQ01-Bodily Pain Subscale Standardized Score: DB Week 48 | -2.72 ± 10.19 | -19.92 ± 13.98 |
| CHQ01-Behavior Subscale Standardized Score: DB Week 24 | 2.33 ± 2.68 | 7.48 ± 2.87 |
| CHQ01-Behavior Subscale Standardized Score: DB Week 48 | -4.50 ± 4.97 | 10.53 ± 5.35 |
| CHQ01-Global Behavior Subscale Standardized Score: DB Week 24 | 4.17 ± 3.89 | 9.48 ± 4.13 |
| CHQ01-Global Behavior Subscale Standardized Score: DB Week 48 | 5.90 ± 4.00 | 13.14 ± 4.54 |
| CHQ01-Mental Health Subscale Standardized Score: DB Week 24 | 6.59 ± 3.56 | 2.14 ± 3.78 |
| CHQ01-Mental Health Subscale Standardized Score: DB Week 48 | 0.79 ± 4.98 | 8.26 ± 5.71 |
| CHQ01-Self Esteem Subscale Standardized Score: DB Week 24 | 6.68 ± 3.05 | 6.69 ± 3.24 |
| CHQ01-Self Esteem Subscale Standardized Score: DB Week 48 | 3.05 ± 7.24 | 10.64 ± 8.04 |
| CHQ01-General Health Subscale Standardized Score: DB Week 24 | 5.02 ± 3.21 | 0.03 ± 3.42 |
| CHQ01-General Health Subscale Standardized Score: DB Week 48 | 9.59 ± 5.20 | 10.60 ± 5.92 |
| CHQ01-Change in Health Subscale Score: DB Week 24 | 0.45 ± 0.12 | 0.48 ± 0.13 |
| CHQ01-Change in Health Subscale Score: DB Week 48 | 0.64 ± 0.32 | 0.16 ± 0.35 |
| CHQ01-Emotion al Impact on Parent Subscale Standardized Score: DB Week 24 | 15.00 ± 4.28 | 12.75 ± 4.53 |
| CHQ01-Emotion al Impact on Parent Subscale Standardized Score: DB Week 48 | 7.15 ± 10.25 | 32.22 ± 11.79 |
| CHQ01-Time Impact on Parent Subscale Standardized Score: DB Week 24 | 7.53 ± 5.10 | 5.66 ± 5.25 |
| CHQ01-Time Impact on Parent Subscale Standardized Score: DB Week 48 | 11.60 ± 8.94 | 20.79 ± 14.05 |
| CHQ01-Family Activities Subscale Standardized Score: DB Week 24 | 5.71 ± 2.96 | 9.68 ± 3.13 |
| CHQ01-Family Activities Subscale Standardized Score: DB Week 48 | 6.65 ± 5.73 | 15.95 ± 7.16 |
| CHQ01-Family Cohesion Subscale Standardized Score: DB Week 24 | 2.84 ± 3.71 | 6.36 ± 3.96 |
| CHQ01-Family Cohesion Subscale Standardized Score: DB Week 48 | -12.24 ± 13.08 | 8.18 ± 15.58 |
For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'no pain' and '10' as 'very severe pain' on a 21-circle VAS, where higher scores indicated more severe pain.
| Units on a scale | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 7 | -1.20 ± 1.77 |
| Part 1 Week 2 | -1.87 ± 2.07 |
| Part 1 Week 4 | -2.57 ± 2.14 |
| Part 1 Week 8 | -3.30 ± 2.45 |
| Part 1 Week 12 | -3.57 ± 2.50 |
| Part 1 Week 16 | -3.69 ± 2.28 |
For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'no pain' and '10' as 'very severe pain' on a 21-circle VAS, where higher scores indicated more pain.
| Units on a scale | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | -4.23 ± 3.14 |
| Part 2 Week 8 | -4.38 ± 2.95 |
| Part 2 Week 12 | -4.42 ± 3.26 |
| Part 2 Week 16 | -4.48 ± 2.88 |
| Part 2 Week 20 | -5.15 ± 3.52 |
| Part 2 Week 24 | -6.00 ± 1.73 |
For the assessment of discomfort, the parent/legal guardian or adult caregiver who interacted daily with the participant were required to rate the overall pain the participant had due to illness by entering a number from 0 to 10 (in 0.5 increments), with '0' as 'no pain' and '10' as 'very severe pain' on a 21-circle VAS, where higher scores indicated more severe pain.
| Units on a scale | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 0.13 ± 0.28 | 0.37 ± 0.26 |
| DB Week 8 | 0.56 ± 0.36 | 0.02 ± 0.35 |
| DB Week 12 | 0.04 ± 0.34 | 0.09 ± 0.32 |
| DB Week 16 | 0.44 ± 0.36 | -0.11 ± 0.35 |
| DB Week 20 | 0.09 ± 0.40 | -0.14 ± 0.42 |
| DB Week 24 | 0.07 ± 0.27 | -0.25 ± 0.28 |
| DB Week 28 | -0.03 ± 0.47 | 0.39 ± 0.51 |
| DB Week 32 | -0.31 ± 0.39 | 0.01 ± 0.42 |
| DB Week 36 | -0.55 ± 0.34 | -0.24 ± 0.37 |
| DB Week 40 | -0.76 ± 0.20 | -0.83 ± 0.21 |
| DB Week 44 | -1.09 ± 0.23 | -0.79 ± 0.24 |
| DB Week 48 | -0.19 ± 0.49 | -0.43 ± 0.79 |
| DB Week 52 | -0.85 ± 0.21 | -0.76 ± 0.34 |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of \<=2.
| Percentage of participants | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 7 | 3.09 (0 to 6.54) |
| Part 1 Week 2 | 5.21 (0.76 to 9.65) |
| Part 1 Week 4 | 6.19 (1.39 to 10.98) |
| Part 1 Week 8 | 13.75 (6.20 to 21.30) |
| Part 1 Week 12 | 13.64 (3.50 to 23.78) |
| Part 1 Week 16 | 25.00 (7.68 to 42.32) |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of \<=2.
| Percentage of participants | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 7 | 1.02 (0 to 3.01) |
| Part 1 Week 2 | 4.08 (0.16 to 8.00) |
| Part 1 Week 4 | 7.22 (2.07 to 12.37) |
| Part 1 Week 8 | 14.81 (7.08 to 22.55) |
| Part 1 Week 12 | 15.91 (5.10 to 26.72) |
| Part 1 Week 16 | 20.83 (4.59 to 37.08) |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of \<=2.
| Percentage of participants | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | 36.00 (22.70 to 49.30) |
| Part 2 Week 8 | 30.00 (15.80 to 44.20) |
| Part 2 Week 12 | 32.26 (15.80 to 48.71) |
| Part 2 Week 16 | 36.36 (16.26 to 56.47) |
| Part 2 Week 20 | 53.85 (26.75 to 80.95) |
| Part 2 Week 24 | 33.33 (0 to 86.68) |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of \<=2.
| Percentage of participants | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | 32.00 (19.07 to 44.93) |
| Part 2 Week 8 | 27.50 (13.66 to 41.34) |
| Part 2 Week 12 | 29.03 (13.05 to 45.01) |
| Part 2 Week 16 | 34.78 (15.32 to 54.25) |
| Part 2 Week 20 | 53.85 (26.75 to 80.95) |
| Part 2 Week 24 | 33.33 (0 to 86.68) |
JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores:more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27,where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57,where higher scores:more disease activity.Inactive disease activity based on JADAS-27 CRP score was defined as: For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of:\<=1.For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of \<=1.
| Percentage of Participants | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 7 | 0 (0 to 0) |
| Part 1 Week 2 | 3.13 (0 to 6.61) |
| Part 1 Week 4 | 3.09 (0 to 6.54) |
| Part 1 Week 8 | 5.00 (0.22 to 9.78) |
| Part 1 Week 12 | 4.55 (0 to 10.70) |
| Part 1 Week 16 | 4.17 (0 to 12.16) |
JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores:more inflammation and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive Disease activity based on JADAS-27 ESR score was defined as for participants with polyarthritis(\>4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of:\<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of \<=1.
| Percentage of Participants | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Part 1 Day 7 | 0 (0 to 0) |
| Part 1 Week 2 | 2.04 (0 to 4.84) |
| Part 1 Week 4 | 1.03 (0 to 3.04) |
| Part 1 Week 8 | 3.70 (0 to 7.82) |
| Part 1 Week 12 | 6.82 (0 to 14.27) |
| Part 1 Week 16 | 4.17 (0 to 12.16) |
JADAS-27 is a validated composite disease activity measure for JIA.Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores: more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27,where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57,where higher scores: more disease activity.Inactive disease activity based on JADAS-27 CRP score was defined as: For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of:\<=1.For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of \<=1.
| Percentage of Participants | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | 16.00 (5.84 to 26.16) |
| Part 2 Week 8 | 20.00 (7.60 to 32.40) |
| Part 2 Week 12 | 9.68 (0 to 20.09) |
| Part 2 Week 16 | 18.18 (2.06 to 34.30) |
| Part 2 Week 20 | 38.46 (12.01 to 64.91) |
| Part 2 Week 24 | 33.33 (0 to 86.68) |
JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores:more inflammation and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive Disease activity based on JADAS-27 ESR score was defined as for participants with polyarthritis(\>4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of:\<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of \<=1.
| Percentage of Participants | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | 16.00 (5.84 to 26.16) |
| Part 2 Week 8 | 17.50 (5.72 to 29.28) |
| Part 2 Week 12 | 9.68 (0 to 20.09) |
| Part 2 Week 16 | 17.39 (1.90 to 32.88) |
| Part 2 Week 20 | 46.15 (19.05 to 73.25) |
| Part 2 Week 24 | 33.33 (0 to 86.68) |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), CRP (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 CRP score of \<=2.
| Percentage of Participants | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 21.43 | 51.61 |
| DB Week 8 | 25.00 | 48.39 |
| DB Week 12 | 32.14 | 32.26 |
| DB Week 16 | 35.71 | 29.03 |
| DB Week 20 | 35.71 | 22.58 |
| DB Week 24 | 35.71 | 35.48 |
| DB Week 28 | 35.71 | 32.26 |
| DB Week 32 | 28.57 | 22.58 |
| DB Week 36 | 39.29 | 35.48 |
| DB Week 40 | 39.29 | 29.03 |
| DB Week 44 | 46.43 | 25.81 |
| DB Week 48 | 46.43 | 25.81 |
| DB Week 52 | 46.43 | 29.03 |
JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score were determined based on four components: Physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores indicated more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores indicated more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores indicated more disease activity. For participants with polyarthritis (\>4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of: \<= 3.8. For participants with oligoarthritis (\<= 4 active joints) minimal disease activity was defined as a JADAS-27 ESR score of \<=2.
| Percentage of Participants | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 25.00 | 51.61 |
| DB Week 8 | 25.00 | 45.16 |
| DB Week 12 | 32.14 | 41.94 |
| DB Week 16 | 35.71 | 35.48 |
| DB Week 20 | 39.29 | 29.03 |
| DB Week 24 | 35.71 | 38.71 |
| DB Week 28 | 35.71 | 38.71 |
| DB Week 32 | 28.57 | 35.48 |
| DB Week 36 | 39.29 | 35.48 |
| DB Week 40 | 39.29 | 32.26 |
| DB Week 44 | 50.00 | 32.26 |
| DB Week 48 | 50.00 | 35.48 |
| DB Week 52 | 50.00 | 32.26 |
JADAS-27 is a validated composite disease activity measure for JIA.Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity); parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor),CRP (value normalized to 0 to 10 scale, where higher scores:more inflammation) and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity).The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive disease activity based on JADAS-27 CRP score was defined as: For participants with polyarthritis (\>4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of:\<=1.For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 CRP score of \<=1.
| Percentage of Participants | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 10.71 | 25.81 |
| DB Week 8 | 7.14 | 19.35 |
| DB Week 12 | 7.14 | 16.13 |
| DB Week 16 | 14.29 | 9.68 |
| DB Week 20 | 14.29 | 9.68 |
| DB Week 24 | 7.14 | 16.13 |
| DB Week 28 | 10.71 | 22.58 |
| DB Week 32 | 14.29 | 19.35 |
| DB Week 36 | 10.71 | 16.13 |
| DB Week 40 | 14.29 | 25.81 |
| DB Week 44 | 14.29 | 16.13 |
| DB Week 48 | 10.71 | 19.35 |
| DB Week 52 | 14.29 | 19.35 |
JADAS-27 is a validated composite disease activity measure for JIA. Score were determined based on four components:physician global assessment of disease activity assessed on a VAS of 0 (no activity) to 10 (maximum activity);parent/legal guardian global assessment of well-being (from the CHAQ assessed on a VAS of 0 (very well) to 10 (very poor), ESR (value normalized to 0 to 10 scale, where higher scores:more inflammation and number of joints with active disease (27 joint assessment ranging from 0 to 27, where higher scores:more disease activity). The overall JADAS-27 score was sum of the 4 components and it ranged from 0 to 57, where higher scores:more disease activity. Inactive Disease activity based on JADAS-27 ESR score was defined as for participants with polyarthritis(\>4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of:\<=1. For participants with oligoarthritis (\<=4 active joints) inactive disease activity was defined as a JADAS-27 ESR score of \<=1.
| Percentage of Participants | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 7.14 | 19.35 |
| DB Week 8 | 14.29 | 29.03 |
| DB Week 12 | 14.29 | 22.58 |
| DB Week 16 | 17.86 | 16.13 |
| DB Week 20 | 14.29 | 12.90 |
| DB Week 24 | 10.71 | 16.13 |
| DB Week 28 | 10.71 | 22.58 |
| DB Week 32 | 14.29 | 19.35 |
| DB Week 36 | 10.71 | 19.35 |
| DB Week 40 | 14.29 | 25.81 |
| DB Week 44 | 14.29 | 22.58 |
| DB Week 48 | 14.29 | 22.58 |
| DB Week 52 | 14.29 | 19.35 |
The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the 21-numbered circle VAS scale used (VAS from 0 to 10), higher scores indicated more disease activity; duration of morning stiffness of \<=15 minutes. 95% CI was based on normal approximation.
| Percentage of Participants | Tofacitinib 5mg BID OL Part 1 |
|---|---|
| Baseline | 0 (0 to 0) |
| Part 1 Day 3 | 0 (0 to 0) |
| Part 1 Day 7 | 0 (0 to 0) |
| Part 1 Week 2 | 2.02 (0 to 4.79) |
| Part 1 Week 4 | 3.09 (0 to 6.54) |
| Part 1 Week 8 | 4.82 (0.21 to 9.43) |
| Part 1 Week 12 | 4.55 (0 to 10.70) |
| Part 1 Week 16 | 4.17 (0 to 12.16) |
The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the 21-numbered circle VAS scale used (VAS from 0 to 10), higher scores indicated more disease activity; duration of morning stiffness of \<=15 minutes. 95% CI was based on normal approximation. 95% CI was based on normal approximation.
| Percentage of participants | Tofacitinib 5mg BID OL Part 2 |
|---|---|
| Part 2 Week 4 | 14.00 (4.38 to 23.62) |
| Part 2 Week 8 | 10.26 (0.73 to 19.78) |
| Part 2 Week 12 | 6.45 (0 to 15.10) |
| Part 2 Week 16 | 13.04 (0 to 26.81) |
| Part 2 Week 20 | 15.38 (0 to 35.00) |
| Part 2 Week 24 | 33.33 (0 to 86.68) |
The ACR clinical inactive disease was defined as follows: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA; no active uveitis; normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA; physician global assessment of disease activity score of 'best possible' on the 21-numbered circle VAS scale used (VAS from 0 to 10), higher scores indicated more disease activity; duration of morning stiffness of \<=15 minutes. 95% CI was based on normal approximation. 95% CI was based on normal approximation.
| Percentage of Participants | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|
| DB Week 4 | 7.14 | 16.13 |
| DB Week 8 | 3.57 | 22.58 |
| DB Week 12 | 7.14 | 22.58 |
| DB Week 16 | 3.57 | 16.13 |
| DB Week 20 | 7.14 | 16.13 |
| DB Week 24 | 7.14 | 19.35 |
| DB Week 28 | 10.71 | 19.35 |
| DB Week 32 | 10.71 | 19.35 |
| DB Week 36 | 14.29 | 16.13 |
| DB Week 40 | 17.86 | 22.58 |
| DB Week 44 | 14.29 | 22.58 |
| DB Week 48 | 17.86 | 22.58 |
| DB Week 52 | 21.43 | 19.35 |
Collected over From dose 1 up to 28 days after end of study treatment (for OL1=maximum duration up to 16 weeks; for OL2= maximum duration up to 24 weeks and for DB=maximum duration up to 248 weeks). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib 5mg BID OL Part 1 | 0/100 (0%) | 7/100 (7%) | 33/100 (33%) |
| Tofacitinib 5mg BID OL Part 2 | 0/54 (0%) | 0/54 (0%) | 15/54 (27.8%) |
| Tofacitinib 5mg BID DB | 0/28 (0%) | 0/28 (0%) | 23/28 (82.1%) |
| Placebo DB | 0/31 (0%) | 2/31 (6.5%) | 25/31 (80.6%) |
| Event | Tofacitinib 5mg BID OL Part 1 | Tofacitinib 5mg BID OL Part 2 | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|---|---|
| NephrolithiasisRenal and urinary disorders | 0/100 | 0/54 | 0/28 | 1/31 |
| BronchitisInfections and infestations | 0/100 | 0/54 | 0/28 | 1/31 |
| Still's diseaseMusculoskeletal and connective tissue disorders | 3/100 | 0/54 | 0/28 | 0/31 |
| OverdoseInjury, poisoning and procedural complications | 1/100 | 0/54 | 0/28 | 0/31 |
| Histiocytic necrotising lymphadenitisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/100 | 0/54 | 0/28 | 0/31 |
| Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/100 | 0/54 | 0/28 | 0/31 |
| Haemophagocytic lymphohistiocytosisImmune system disorders | 1/100 | 0/54 | 0/28 | 0/31 |
| DepressionPsychiatric disorders | 1/100 | 0/54 | 0/28 | 0/31 |
| Event | Tofacitinib 5mg BID OL Part 1 | Tofacitinib 5mg BID OL Part 2 | Tofacitinib 5mg BID DB | Placebo DB |
|---|---|---|---|---|
| Still's diseaseMusculoskeletal and connective tissue disorders | 0/100 | 3/54 | 8/28 | 14/31 |
| Upper respiratory tract infectionInfections and infestations | 10/100 | 7/54 | 3/28 | 5/31 |
| PyrexiaGeneral disorders | 6/100 | 2/54 | 4/28 | 1/31 |
| VomitingGastrointestinal disorders | 3/100 | 0/54 | 3/28 | 1/31 |
| Urinary tract infectionInfections and infestations | 3/100 | 0/54 | 0/28 | 3/31 |
| COVID-19Infections and infestations | 0/100 | 5/54 | 0/28 | 2/31 |
| NasopharyngitisInfections and infestations | 6/100 | 0/54 | 2/28 | 1/31 |
| Haemoglobin decreasedInvestigations | 0/100 | 0/54 | 2/28 | 0/31 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/100 | 0/54 | 2/28 | 0/31 |
| FallInjury, poisoning and procedural complications | 0/100 | 0/54 | 2/28 | 0/31 |
| Age, Customized(Participants) | Overall |
|---|---|
| 2 to less than (<) 6 Years | 17 |
| 6 to < 12 Years | 43 |
| 12 to < 18 Years | 40 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 44 |
| Male | 56 |
| Race/Ethnicity, Customized(Participants) | Overall |
|---|---|
| Race — White | 39 |
| Race — Black or African American | 7 |
| Race — Asian | 49 |
| Race — Other | 5 |
| Race/Ethnicity, Customized(Participants) | Overall |
|---|---|
| Ethnicity — Hispanic or Latino | 14 |
| Ethnicity — Not Hispanic or Latino | 86 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from May 2018 to primary completion in Mar 2024, 70 months.
Results were first posted in Jun 2025, 1 year 2 months after primary completion.
Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 70 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib